CANbridge doses first patient in phase 2 EMBARK study of CAN108 in BA
CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary atresia (BA) in China. The clinical trial ... Read More
Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome
Mirum Pharmaceuticals has secured the breakthrough therapy designation for maralixibat from the US Food and Drug Administration (FDA) for the treatment of pruritus associated with ... Read More
Mirum Pharmaceuticals raises $120m to advance Maralixibat for rare liver diseases
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to propel the development of its lead drug, ... Read More